The 2025 MIT AI Conference will analyze the latest AI trends, groundbreaking developments, and their profound implications for the future of knowledge, work, skills, and intelligence.
MIT Startup Exchange is looking for two startup speakers for our upcoming Leading Edge webinar, "Securing the Future: AI-Driven, Post-Quantum Data Privacy," taking place on Thursday, October 9, from 11 AM to 12 PM ET. Join experts from MIT, SCBX, and Zcash to showcase your innovations at the intersection of AI, encrypted computation, and post-quantum security. If you're building breakthrough tech in FHE, ZKPs, or privacy-preserving AI.
MIT Startup Exchange Live Demo Day: April 2, 2025
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Covariance’s next-generation external intelligence platform reveals never-before-seen detail on competitors and customers
Predictive Voice AI Empowering Workers’ Safety and Health Yujie Wang Founder & CEO, Vocadian
MIT STARTUP EXCHANGE FEBRUARY 2025 DEMO DAY
February 27, 2025
Lighty AI, Your AI Agent to Help You Navigate Your Workday Richard Rabbat Co-Founder & CEO, Lighty AI